Videos

Sam Amin, MD, discusses how phase 3 findings may influence CDD treatment approaches, while emphasizing the need for long-term safety and efficacy data to better define fenfluramine’s role in clinical practice.

Mitzi Joi Williams, MD, sits down with Sheree Love and Mana Opang Owusu to discuss how movement supports brain health, function, and quality of life for people living with neurologic conditions.

Welcome back to another Neurology Live Peer Exchange series. In this episode titled, “Recognizing Dravet Syndrome in Patients with Unexplained Epilepsy,” expert faculty discuss the burden and heterogeneity of epilepsy and the challenges clinicians face when evaluating patients with unexplained seizures.

The professor of neurology and pediatrics at Vanderbilt University Medical Center discussed her advocacy for sleep health, especially for pediatric patients and their families, at SLEEP 2026. [WATCH TIME: 5 minutes]

AT ATMRD 2026, the CEO and founder of Yes, and... X discussed why social connection and support groups should be viewed as critical components of Parkinson disease care, alongside traditional medical management. [WATCH TIME: 3 minutes]

The discussion shifts toward the biologic rationale behind vorasidenib, exploring how mutant IDH inhibition may simultaneously target tumor growth and seizure activity in patients with IDH-mutant glioma.

At SLEEP 2026, the section chief in the Division of Pulmonary Critical Care and Sleep Medicine at West Virginia University discussed the high burden of undiagnosed sleep apnea in hospitalized patients. [WATCH TIME: 5 minutes]

Discover how a continuous apomorphine pump reduces Parkinson’s “off” time—and why tracking symptoms with a care partner transforms daily life.

Brett Morrison, MD, PhD, associate professor at Johns Hopkins University, discussed the current landscape of biomarkers in peripheral nerve disorders and the evolving role of neurofilament light chain in clinical care and research. [WATCH TIME: 3 minutes]

In this episode focused on first-line MS treatments, Dr. Williams poses the practical question: when a newly diagnosed, treatment-naive patient with relapsing-remitting MS sits across from you, what guides your treatment recommendation?

How MS therapy choices balance patient preference, payer coverage, dosing convenience, and family planning as high-efficacy options expand.

The senior vice president for research at the Kessler Foundation discussed findings showing associations between reductions in neurofilament light chain and gains in cognitive processing speed, verbal memory, and visual memory in patients with early relapsing multiple sclerosis treated with ozanimod. [WATCH TIME: 3 minutes]

Experts weigh CIDP care: IVIG limits, emerging therapies, early-yet-accurate diagnosis, objective response checks, and screening for paraproteins.

Epileptologist Sam Amin, MD, reviews the safety and tolerability findings from the phase 3 fenfluramine study in CDKL5 deficiency disorder, including treatment-emergent adverse events and the absence of major cardiovascular complications.

The associate professor of neurology at Northwestern University Feinberg School of Medicine reviewed key aspects of the 2026 AHA/ASA stroke guidelines in acute ischemic stroke. [WATCH TIME: 5 minutes]

The associate professor of neurology at Mayo Clinic College of Medicine highlighted emerging migraine targets, repurposed therapies, and growing emphasis on patient-reported outcomes beyond monthly migraine days. [WATCH TIME: 3 minutes]

The new president of Consortium of Multiple Sclerosis Centers (CMSC) discussed key themes in multiple sclerosis care presented at the 2026 CMSC Annual Meeting. [WATCH TIME: 11 minutes]

The discussion opens with a broad overview of seizure burden in grade 2 IDH-mutant glioma, highlighting how epilepsy affects quality of life, long-term disease management, and day-to-day functioning throughout the disease course.

At ATMRD 2026, the director of the Parkinson's Disease and Movement Disorders Program at the Cleveland Clinic discussed the importance of movement phenomenology and accurate diagnosis in guiding treatment decisions for patients with hyperkinetic disorders. [WATCH TIME: 7 minutes]

A Parkinson’s patient reveals how off times, med trials and a continuous pump strain family life—and how advocacy brings stability.

At ATMRD 2026, the professor of neurology at Georgetown University Medical Center discussed how clinicians can distinguish Alzheimer disease from Lewy body dementia. [WATCH TIME: 5 minutes]

A Parkinson’s patient explains how a daily apomorphine pump smooths off time, cuts levodopa, and restores confidence, work, and social life.

In this episode, panelists explore the question of "MS Treatment Strategy: High-Efficacy Therapy vs. Escalation Approach." Dr. Williams frames the central question: with earlier MS diagnoses now possible, how has treatment philosophy shifted? The traditional "start low, go slow" escalation model has given way to a high-efficacy-first approach for many clinicians.

Welcome back to another Neurology Live Peer Exchange series. In this episode titled "Evolving MS Diagnostic Criteria: 2024 McDonald Criteria and What's New," moderator Dr. Mitzi Joi Williams discusses multiple sclerosis with Dr. Stephen Krieger.

The CEO and founder of Yes, And...eXercise (YAX) discussed how support groups, psychosocial connection, and hybrid telehealth models can complement pharmacologic treatment in Parkinson disease. [WATCH TIME: 3 minutes]

In this final episode, Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, discuss why neurologists should stay informed on stem cell medicine and the broader implications of regenerative therapies across neurology.

Neurology News Network for the week ending June 6th, 2026. [WATCH TIME: 5 minutes]

The professor of neurology at the University of Colorado discussed evidence from DISCOMS and other trials on disease-modifying therapy discontinuation in older, stable patients with multiple sclerosis. [WATCH TIME: 8 minutes]

Clinicians explain long-term CIDP care: set expectations for ongoing therapy, taper safely, reassess often, and add rehab, mental health, nutrition.

Learn how clinicians partner with CIDP patients to choose IVIG, steroids or SCIG, set expectations, and tailor treatment to real life.